×

Composition and method for treatment of depression and psychosis in humans

  • US 9,737,531 B2
  • Filed: 07/07/2013
  • Issued: 08/22/2017
  • Est. Priority Date: 07/12/2012
  • Status: Active Grant
First Claim
Patent Images

1. A composition for treating depression or psychosis with reduced akathisia side effects in a human in need of such treatment consisting essentially of:

  • an akathisia-producing effective amount of a first compound consisting of a selective 5-HT2A receptor antagonist/inverse agonist selected from the group consisting of eplivanserin (SR46.349) and pimavanserin (ACP-103); and

    an effective amount of a second compound consisting of a selective NMDAR receptor antagonist, selected from the group consisting of D-CPPene and gavestinel,wherein the composition is formulated as a tablet or capsule for systemic oral administration,wherein the selective NMDAR receptor antagonist is a full NMDAR receptor antagonist;

    wherein the effective amount of the selective NMDAR receptor antagonist is sufficient to inhibit the akathisia-producing side effects of the first compound; and

    wherein the NMDAR receptor antagonist binds to at least one of the glycine or glutamate binding sites.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×